Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 84 | 2023 | 11126 | 2.960 |
Why?
|
Testicular Neoplasms | 9 | 2023 | 806 | 2.960 |
Why?
|
Seminoma | 4 | 2023 | 139 | 2.500 |
Why?
|
Carcinoma, Embryonal | 3 | 2023 | 38 | 1.930 |
Why?
|
Prostate | 18 | 2023 | 1775 | 1.540 |
Why?
|
Immunohistochemistry | 36 | 2022 | 11366 | 1.520 |
Why?
|
Kidney Neoplasms | 24 | 2024 | 4262 | 1.410 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 3 | 2022 | 501 | 1.270 |
Why?
|
Carcinoma, Renal Cell | 18 | 2024 | 3143 | 1.220 |
Why?
|
Prostatic Intraepithelial Neoplasia | 4 | 2017 | 76 | 0.960 |
Why?
|
Urinary Bladder Neoplasms | 11 | 2023 | 2249 | 0.940 |
Why?
|
DNA, Neoplasm | 5 | 2016 | 1758 | 0.900 |
Why?
|
Endodermal Sinus Tumor | 1 | 2023 | 47 | 0.880 |
Why?
|
Gene Expression Regulation, Neoplastic | 25 | 2023 | 8432 | 0.880 |
Why?
|
Carcinoma, Transitional Cell | 7 | 2023 | 808 | 0.830 |
Why?
|
Urologic Neoplasms | 3 | 2022 | 318 | 0.820 |
Why?
|
Neoplasms, Complex and Mixed | 1 | 2021 | 31 | 0.790 |
Why?
|
Testis | 4 | 2022 | 804 | 0.780 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2021 | 223 | 0.750 |
Why?
|
Antigens, CD34 | 2 | 2022 | 659 | 0.740 |
Why?
|
Prostatectomy | 17 | 2021 | 1890 | 0.730 |
Why?
|
Carcinoma, Hepatocellular | 10 | 2019 | 2214 | 0.680 |
Why?
|
Neoplasm Proteins | 5 | 2023 | 3707 | 0.680 |
Why?
|
Neoplasm Staging | 34 | 2022 | 11031 | 0.670 |
Why?
|
Polymerase Chain Reaction | 8 | 2016 | 6171 | 0.660 |
Why?
|
Lung Neoplasms | 17 | 2022 | 13104 | 0.650 |
Why?
|
Melanoma | 9 | 2023 | 5511 | 0.630 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 11 | 2022 | 5223 | 0.620 |
Why?
|
Cysts | 1 | 2023 | 678 | 0.620 |
Why?
|
Male | 175 | 2023 | 350115 | 0.610 |
Why?
|
Liver Neoplasms | 12 | 2019 | 4253 | 0.600 |
Why?
|
Lymphatic Vessels | 1 | 2021 | 353 | 0.590 |
Why?
|
Oncogene Proteins, Fusion | 11 | 2023 | 1581 | 0.580 |
Why?
|
Liver Transplantation | 10 | 2014 | 2119 | 0.570 |
Why?
|
Ovarian Neoplasms | 6 | 2023 | 4839 | 0.540 |
Why?
|
Gastrointestinal Stromal Tumors | 6 | 2019 | 643 | 0.540 |
Why?
|
Prostate-Specific Antigen | 13 | 2022 | 2494 | 0.530 |
Why?
|
Aged | 118 | 2023 | 163288 | 0.530 |
Why?
|
Mutation | 27 | 2024 | 29786 | 0.520 |
Why?
|
Frozen Sections | 3 | 2021 | 155 | 0.520 |
Why?
|
High-Throughput Nucleotide Sequencing | 7 | 2023 | 3595 | 0.520 |
Why?
|
In Situ Hybridization, Fluorescence | 8 | 2020 | 2649 | 0.510 |
Why?
|
Middle Aged | 123 | 2022 | 213390 | 0.500 |
Why?
|
Humans | 228 | 2024 | 744366 | 0.500 |
Why?
|
Lymph Nodes | 7 | 2022 | 3476 | 0.470 |
Why?
|
Neoplasm Invasiveness | 7 | 2023 | 3616 | 0.470 |
Why?
|
BRCA1 Protein | 4 | 2023 | 1149 | 0.470 |
Why?
|
Carcinoma, Squamous Cell | 7 | 2021 | 4034 | 0.460 |
Why?
|
Pathology, Molecular | 1 | 2016 | 326 | 0.460 |
Why?
|
Penile Neoplasms | 3 | 2021 | 161 | 0.460 |
Why?
|
Serine Endopeptidases | 6 | 2023 | 1073 | 0.430 |
Why?
|
Prognosis | 38 | 2023 | 29060 | 0.430 |
Why?
|
Forkhead Transcription Factors | 2 | 2017 | 1613 | 0.430 |
Why?
|
Tissue Donors | 5 | 2009 | 2241 | 0.420 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 5 | 2019 | 378 | 0.410 |
Why?
|
Proto-Oncogene Proteins c-kit | 6 | 2020 | 776 | 0.410 |
Why?
|
DNA Mutational Analysis | 6 | 2021 | 4185 | 0.410 |
Why?
|
Carcinoma | 5 | 2021 | 2375 | 0.410 |
Why?
|
Muscle, Smooth | 1 | 2016 | 934 | 0.400 |
Why?
|
Receptor, erbB-2 | 5 | 2021 | 2417 | 0.390 |
Why?
|
Proto-Oncogene Proteins c-met | 5 | 2021 | 578 | 0.390 |
Why?
|
beta Catenin | 4 | 2013 | 1059 | 0.390 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 5 | 2015 | 4751 | 0.380 |
Why?
|
Retrospective Studies | 45 | 2024 | 77460 | 0.380 |
Why?
|
Cystectomy | 1 | 2016 | 686 | 0.370 |
Why?
|
Telomerase | 3 | 2023 | 730 | 0.370 |
Why?
|
Skin Neoplasms | 9 | 2023 | 5692 | 0.370 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 12 | 2022 | 11525 | 0.360 |
Why?
|
Neoplasm Recurrence, Local | 15 | 2022 | 9240 | 0.360 |
Why?
|
Neoplasm Metastasis | 12 | 2021 | 4851 | 0.350 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2020 | 2043 | 0.340 |
Why?
|
Protein Kinase Inhibitors | 11 | 2024 | 5534 | 0.340 |
Why?
|
Adult | 80 | 2021 | 214052 | 0.340 |
Why?
|
Primary Graft Dysfunction | 1 | 2009 | 93 | 0.330 |
Why?
|
Aged, 80 and over | 41 | 2021 | 57776 | 0.330 |
Why?
|
Wnt1 Protein | 1 | 2008 | 118 | 0.320 |
Why?
|
Italy | 8 | 2021 | 832 | 0.320 |
Why?
|
TOR Serine-Threonine Kinases | 7 | 2023 | 2110 | 0.320 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 4 | 2020 | 1038 | 0.320 |
Why?
|
Prostatitis | 2 | 2019 | 102 | 0.310 |
Why?
|
Palmitic Acid | 1 | 2008 | 154 | 0.310 |
Why?
|
Nevus | 2 | 2022 | 204 | 0.310 |
Why?
|
Quinazolines | 1 | 2014 | 1356 | 0.300 |
Why?
|
Urogenital Neoplasms | 2 | 2020 | 137 | 0.300 |
Why?
|
Observer Variation | 7 | 2022 | 2593 | 0.300 |
Why?
|
Choline | 3 | 2021 | 493 | 0.290 |
Why?
|
Thyroid Neoplasms | 3 | 2016 | 2282 | 0.280 |
Why?
|
Electron Transport Complex II | 3 | 2018 | 48 | 0.280 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2017 | 2988 | 0.280 |
Why?
|
Hematoxylin | 2 | 2023 | 64 | 0.280 |
Why?
|
Eosine Yellowish-(YS) | 2 | 2023 | 72 | 0.280 |
Why?
|
Cytoplasm | 3 | 2016 | 1536 | 0.280 |
Why?
|
Genes, BRCA1 | 1 | 2010 | 781 | 0.270 |
Why?
|
Follow-Up Studies | 29 | 2023 | 39052 | 0.270 |
Why?
|
Survival Analysis | 14 | 2022 | 10252 | 0.270 |
Why?
|
Urothelium | 2 | 2021 | 277 | 0.270 |
Why?
|
Antigens, Neoplasm | 4 | 2022 | 1988 | 0.260 |
Why?
|
Female | 86 | 2023 | 380193 | 0.260 |
Why?
|
Proto-Oncogene Proteins | 5 | 2022 | 4554 | 0.260 |
Why?
|
Gastrointestinal Neoplasms | 3 | 2019 | 990 | 0.260 |
Why?
|
Predictive Value of Tests | 13 | 2021 | 15078 | 0.260 |
Why?
|
Tumor Burden | 4 | 2020 | 1915 | 0.260 |
Why?
|
Trans-Activators | 4 | 2016 | 2926 | 0.250 |
Why?
|
Disease Progression | 18 | 2020 | 13286 | 0.250 |
Why?
|
Adenocarcinoma | 9 | 2018 | 6364 | 0.250 |
Why?
|
Carboplatin | 3 | 2014 | 801 | 0.240 |
Why?
|
Gene Expression Profiling | 9 | 2023 | 9445 | 0.240 |
Why?
|
Tumor Suppressor Proteins | 4 | 2019 | 2850 | 0.240 |
Why?
|
Tissue Array Analysis | 3 | 2021 | 553 | 0.230 |
Why?
|
Sequence Deletion | 2 | 2019 | 1525 | 0.230 |
Why?
|
Fatty Liver | 1 | 2009 | 727 | 0.230 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2008 | 484 | 0.230 |
Why?
|
Glypicans | 1 | 2023 | 34 | 0.230 |
Why?
|
Receptors, Adiponectin | 2 | 2015 | 82 | 0.230 |
Why?
|
Neoplastic Processes | 1 | 2023 | 35 | 0.220 |
Why?
|
Robotics | 2 | 2021 | 899 | 0.220 |
Why?
|
Atrophy | 3 | 2019 | 1584 | 0.220 |
Why?
|
In Situ Hybridization | 4 | 2021 | 1950 | 0.220 |
Why?
|
Lymphatic Metastasis | 7 | 2021 | 2924 | 0.220 |
Why?
|
Watchful Waiting | 4 | 2021 | 492 | 0.220 |
Why?
|
Patient Selection | 5 | 2018 | 4216 | 0.220 |
Why?
|
alpha-Fetoproteins | 1 | 2023 | 224 | 0.220 |
Why?
|
Prospective Studies | 28 | 2021 | 53290 | 0.210 |
Why?
|
Biopsy | 12 | 2022 | 6755 | 0.200 |
Why?
|
Carcinoma, Papillary | 3 | 2017 | 783 | 0.200 |
Why?
|
PTEN Phosphohydrolase | 4 | 2017 | 1142 | 0.200 |
Why?
|
Survival Rate | 13 | 2021 | 12788 | 0.200 |
Why?
|
Orchiectomy | 4 | 2020 | 474 | 0.200 |
Why?
|
Adenoma, Sweat Gland | 1 | 2021 | 18 | 0.200 |
Why?
|
Platinum Compounds | 1 | 2022 | 96 | 0.200 |
Why?
|
Acrospiroma | 1 | 2021 | 13 | 0.200 |
Why?
|
Inflammation | 6 | 2023 | 10637 | 0.190 |
Why?
|
Hematopoietic System | 1 | 2021 | 109 | 0.190 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2019 | 2455 | 0.190 |
Why?
|
Leydig Cell Tumor | 1 | 2020 | 25 | 0.190 |
Why?
|
Neoplasms, Bone Tissue | 1 | 2020 | 7 | 0.190 |
Why?
|
Activins | 1 | 2022 | 208 | 0.190 |
Why?
|
Crohn Disease | 3 | 2020 | 2304 | 0.190 |
Why?
|
Molecular Targeted Therapy | 5 | 2019 | 2725 | 0.180 |
Why?
|
Early Detection of Cancer | 1 | 2014 | 3086 | 0.180 |
Why?
|
Neoplasms | 7 | 2019 | 21696 | 0.180 |
Why?
|
Succinate Dehydrogenase | 3 | 2019 | 146 | 0.180 |
Why?
|
Graft Survival | 2 | 2009 | 3737 | 0.180 |
Why?
|
GTP Phosphohydrolases | 2 | 2020 | 508 | 0.180 |
Why?
|
Paraffin Embedding | 3 | 2018 | 299 | 0.180 |
Why?
|
5' Flanking Region | 1 | 2019 | 31 | 0.180 |
Why?
|
RNA, Viral | 4 | 2020 | 2901 | 0.180 |
Why?
|
Tissue Fixation | 3 | 2018 | 241 | 0.180 |
Why?
|
Genes, BRCA2 | 1 | 2023 | 618 | 0.180 |
Why?
|
Algorithms | 2 | 2020 | 13882 | 0.170 |
Why?
|
Fibroblast Growth Factor 4 | 1 | 2019 | 27 | 0.170 |
Why?
|
Environment | 2 | 2023 | 1123 | 0.170 |
Why?
|
Sweat Gland Neoplasms | 1 | 2021 | 108 | 0.170 |
Why?
|
Kaplan-Meier Estimate | 8 | 2022 | 6539 | 0.170 |
Why?
|
Formaldehyde | 3 | 2018 | 353 | 0.170 |
Why?
|
Receptors, Somatomedin | 1 | 2018 | 57 | 0.170 |
Why?
|
Treatment Outcome | 21 | 2020 | 63107 | 0.170 |
Why?
|
Hematuria | 1 | 2020 | 235 | 0.170 |
Why?
|
Endosonography | 2 | 2020 | 610 | 0.160 |
Why?
|
Proportional Hazards Models | 11 | 2019 | 12356 | 0.160 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2022 | 5172 | 0.160 |
Why?
|
Hepacivirus | 3 | 2013 | 1379 | 0.160 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2019 | 934 | 0.160 |
Why?
|
Antioxidants | 2 | 2017 | 1659 | 0.160 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2023 | 2949 | 0.160 |
Why?
|
Nevus, Pigmented | 1 | 2020 | 219 | 0.160 |
Why?
|
Fluorouracil | 3 | 1992 | 1619 | 0.160 |
Why?
|
Antineoplastic Agents | 7 | 2019 | 13693 | 0.160 |
Why?
|
Gene Amplification | 2 | 2021 | 1063 | 0.160 |
Why?
|
Hodgkin Disease | 2 | 2017 | 1415 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2020 | 381 | 0.160 |
Why?
|
Gene Duplication | 1 | 2019 | 329 | 0.150 |
Why?
|
Receptors, Androgen | 5 | 2021 | 1058 | 0.150 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2019 | 535 | 0.150 |
Why?
|
Carmustine | 1 | 1997 | 137 | 0.150 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2022 | 1660 | 0.150 |
Why?
|
Hepatitis C | 4 | 2013 | 1591 | 0.150 |
Why?
|
Mitoxantrone | 2 | 1995 | 152 | 0.150 |
Why?
|
Radiology Information Systems | 1 | 2022 | 523 | 0.150 |
Why?
|
DNA Fragmentation | 1 | 2017 | 242 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2020 | 539 | 0.150 |
Why?
|
Immunotherapy | 4 | 2022 | 4446 | 0.150 |
Why?
|
DNA Modification Methylases | 1 | 2017 | 206 | 0.150 |
Why?
|
Ki-67 Antigen | 4 | 2015 | 644 | 0.140 |
Why?
|
Angiomyolipoma | 2 | 2015 | 190 | 0.140 |
Why?
|
Bone Neoplasms | 2 | 2019 | 2530 | 0.140 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2019 | 602 | 0.140 |
Why?
|
Nucleic Acids | 1 | 2018 | 182 | 0.140 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2019 | 449 | 0.140 |
Why?
|
Carcinoma in Situ | 1 | 2022 | 806 | 0.140 |
Why?
|
Breast Neoplasms | 7 | 2017 | 20824 | 0.140 |
Why?
|
Pathology, Clinical | 1 | 2020 | 368 | 0.140 |
Why?
|
BRCA2 Protein | 2 | 2023 | 794 | 0.130 |
Why?
|
Nephrectomy | 2 | 2019 | 1050 | 0.130 |
Why?
|
DNA Repair Enzymes | 1 | 2017 | 349 | 0.130 |
Why?
|
Reproducibility of Results | 11 | 2022 | 19905 | 0.130 |
Why?
|
Membrane Proteins | 5 | 2020 | 7882 | 0.130 |
Why?
|
Disease Susceptibility | 2 | 2019 | 1782 | 0.130 |
Why?
|
RNA, Neoplasm | 2 | 2015 | 769 | 0.130 |
Why?
|
Nonsteroidal Anti-Androgens | 1 | 2015 | 8 | 0.130 |
Why?
|
Receptor, IGF Type 1 | 2 | 2018 | 390 | 0.130 |
Why?
|
Anilides | 1 | 2018 | 408 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-myb | 1 | 2015 | 78 | 0.130 |
Why?
|
Risk Assessment | 11 | 2020 | 23336 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2022 | 3480 | 0.130 |
Why?
|
Estrogen Receptor alpha | 2 | 2017 | 577 | 0.130 |
Why?
|
ROC Curve | 5 | 2018 | 3528 | 0.130 |
Why?
|
Mutation, Missense | 2 | 2018 | 2566 | 0.130 |
Why?
|
Chemoembolization, Therapeutic | 2 | 2014 | 129 | 0.130 |
Why?
|
Brain Neoplasms | 4 | 2010 | 8861 | 0.130 |
Why?
|
Cystadenocarcinoma, Papillary | 1 | 1995 | 59 | 0.130 |
Why?
|
Lymph Node Excision | 3 | 2020 | 1262 | 0.130 |
Why?
|
Preoperative Care | 4 | 2014 | 2251 | 0.130 |
Why?
|
Chromosome Deletion | 1 | 2019 | 1401 | 0.120 |
Why?
|
Receptor, Insulin | 1 | 2018 | 847 | 0.120 |
Why?
|
Receptors, Progesterone | 2 | 2017 | 1098 | 0.120 |
Why?
|
Nevus, Epithelioid and Spindle Cell | 1 | 2015 | 68 | 0.120 |
Why?
|
Serotonin | 2 | 2016 | 1017 | 0.120 |
Why?
|
Intestines | 2 | 2017 | 1924 | 0.120 |
Why?
|
Adenoma, Oxyphilic | 1 | 2015 | 143 | 0.120 |
Why?
|
Sweden | 4 | 2019 | 1341 | 0.120 |
Why?
|
Magnetic Resonance Imaging | 7 | 2022 | 35425 | 0.120 |
Why?
|
Plaque, Amyloid | 1 | 2018 | 729 | 0.120 |
Why?
|
Astrocytoma | 1 | 1999 | 790 | 0.120 |
Why?
|
Cisplatin | 5 | 1996 | 1662 | 0.120 |
Why?
|
Matched-Pair Analysis | 1 | 2014 | 288 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2019 | 988 | 0.120 |
Why?
|
Specimen Handling | 1 | 2018 | 694 | 0.120 |
Why?
|
Antibodies, Monoclonal | 3 | 2022 | 9274 | 0.120 |
Why?
|
Time Factors | 8 | 2018 | 40075 | 0.110 |
Why?
|
DNA Repair | 2 | 2020 | 2046 | 0.110 |
Why?
|
Amyloidosis | 1 | 2020 | 796 | 0.110 |
Why?
|
Case-Control Studies | 10 | 2019 | 21748 | 0.110 |
Why?
|
Inguinal Canal | 1 | 2013 | 69 | 0.110 |
Why?
|
Cyclin D1 | 1 | 2015 | 463 | 0.110 |
Why?
|
Glioma | 3 | 2009 | 3401 | 0.110 |
Why?
|
Esophagus | 1 | 2019 | 1019 | 0.110 |
Why?
|
Exercise | 2 | 2021 | 5615 | 0.110 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 1997 | 627 | 0.110 |
Why?
|
Renal Veins | 1 | 2013 | 108 | 0.110 |
Why?
|
Peripheral Nerves | 1 | 2017 | 466 | 0.110 |
Why?
|
Young Adult | 11 | 2021 | 56429 | 0.110 |
Why?
|
Abdominal Pain | 1 | 2020 | 1064 | 0.110 |
Why?
|
Interferon-alpha | 1 | 1997 | 895 | 0.110 |
Why?
|
Genital Neoplasms, Male | 1 | 2013 | 74 | 0.110 |
Why?
|
Cadaver | 2 | 2009 | 1337 | 0.110 |
Why?
|
Metabolome | 1 | 2019 | 895 | 0.110 |
Why?
|
Elasticity Imaging Techniques | 1 | 2017 | 388 | 0.110 |
Why?
|
Liver | 5 | 2010 | 7475 | 0.110 |
Why?
|
Exons | 2 | 2015 | 2439 | 0.110 |
Why?
|
Carotenoids | 1 | 2016 | 624 | 0.110 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2018 | 477 | 0.110 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2016 | 324 | 0.100 |
Why?
|
Intestinal Mucosa | 4 | 2017 | 3037 | 0.100 |
Why?
|
Radiopharmaceuticals | 3 | 2018 | 2645 | 0.100 |
Why?
|
Metabolomics | 1 | 2020 | 1485 | 0.100 |
Why?
|
Stromal Cells | 1 | 2017 | 1355 | 0.100 |
Why?
|
Gonadal Steroid Hormones | 1 | 2016 | 711 | 0.100 |
Why?
|
Intestinal Neoplasms | 1 | 2014 | 319 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2017 | 2938 | 0.100 |
Why?
|
Organic Anion Transporters, Sodium-Independent | 1 | 2011 | 24 | 0.100 |
Why?
|
Head and Neck Neoplasms | 2 | 2020 | 2736 | 0.100 |
Why?
|
Neuroendocrine Tumors | 1 | 2017 | 594 | 0.100 |
Why?
|
Neovascularization, Pathologic | 3 | 2016 | 2638 | 0.100 |
Why?
|
Sensitivity and Specificity | 7 | 2018 | 14723 | 0.100 |
Why?
|
Central Nervous System Neoplasms | 1 | 2019 | 895 | 0.100 |
Why?
|
Thromboembolism | 1 | 1997 | 987 | 0.100 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2019 | 1524 | 0.090 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2018 | 2016 | 0.090 |
Why?
|
Remission Induction | 5 | 1997 | 2385 | 0.090 |
Why?
|
Organic Anion Transporters | 1 | 2011 | 100 | 0.090 |
Why?
|
Neoadjuvant Therapy | 2 | 2014 | 2727 | 0.090 |
Why?
|
Fibrosis | 1 | 2017 | 2029 | 0.090 |
Why?
|
Leucovorin | 1 | 1992 | 628 | 0.090 |
Why?
|
CA-125 Antigen | 2 | 2008 | 286 | 0.090 |
Why?
|
Bronchoscopy | 3 | 2021 | 862 | 0.090 |
Why?
|
Cell Line, Transformed | 2 | 2009 | 898 | 0.090 |
Why?
|
RNA | 2 | 2017 | 2749 | 0.090 |
Why?
|
Immunomagnetic Separation | 1 | 2010 | 80 | 0.090 |
Why?
|
Irritable Bowel Syndrome | 1 | 2016 | 445 | 0.090 |
Why?
|
Multivariate Analysis | 5 | 2014 | 12244 | 0.090 |
Why?
|
Signal Transduction | 10 | 2022 | 23404 | 0.090 |
Why?
|
Deoxycytidine | 1 | 2014 | 826 | 0.090 |
Why?
|
Genes, erbB-2 | 1 | 2010 | 162 | 0.090 |
Why?
|
Thymoma | 1 | 1991 | 186 | 0.090 |
Why?
|
Adolescent | 16 | 2020 | 85779 | 0.090 |
Why?
|
MicroRNAs | 2 | 2018 | 3751 | 0.090 |
Why?
|
Celiac Disease | 1 | 2017 | 785 | 0.090 |
Why?
|
DNA Methylation | 2 | 2017 | 4285 | 0.090 |
Why?
|
Gastrointestinal Tract | 1 | 2016 | 814 | 0.090 |
Why?
|
Coloring Agents | 2 | 2022 | 566 | 0.090 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2017 | 3921 | 0.090 |
Why?
|
Adiponectin | 2 | 2015 | 1101 | 0.090 |
Why?
|
Lymphocytes | 1 | 2017 | 2617 | 0.090 |
Why?
|
Molecular Imaging | 1 | 2016 | 828 | 0.090 |
Why?
|
Up-Regulation | 5 | 2020 | 4222 | 0.080 |
Why?
|
Gene Fusion | 1 | 2012 | 371 | 0.080 |
Why?
|
S-Phase Kinase-Associated Proteins | 1 | 2009 | 90 | 0.080 |
Why?
|
Lymphangioleiomyomatosis | 1 | 2011 | 210 | 0.080 |
Why?
|
Liver Cirrhosis | 3 | 2010 | 1862 | 0.080 |
Why?
|
RNA, Messenger | 6 | 2019 | 13035 | 0.080 |
Why?
|
Thymus Neoplasms | 1 | 1991 | 268 | 0.080 |
Why?
|
Receptors, Calcitriol | 1 | 2011 | 348 | 0.080 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2023 | 705 | 0.080 |
Why?
|
Prostatic Hyperplasia | 2 | 2011 | 523 | 0.080 |
Why?
|
Apoptosis | 6 | 2018 | 9724 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2460 | 0.080 |
Why?
|
Wnt Proteins | 1 | 2012 | 721 | 0.080 |
Why?
|
Endoribonucleases | 1 | 2010 | 229 | 0.080 |
Why?
|
Hepatitis C Antigens | 1 | 2008 | 34 | 0.080 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2022 | 710 | 0.080 |
Why?
|
Esophageal Neoplasms | 1 | 2018 | 1585 | 0.080 |
Why?
|
Hepatitis | 1 | 2010 | 227 | 0.080 |
Why?
|
Glutathione S-Transferase pi | 1 | 2008 | 97 | 0.080 |
Why?
|
Carrier Proteins | 2 | 2014 | 5023 | 0.080 |
Why?
|
DNA Copy Number Variations | 4 | 2019 | 1941 | 0.080 |
Why?
|
Perforin | 1 | 2008 | 168 | 0.080 |
Why?
|
Stress, Physiological | 1 | 2015 | 1403 | 0.080 |
Why?
|
Area Under Curve | 2 | 2012 | 1655 | 0.080 |
Why?
|
Endothelial Cells | 1 | 2020 | 3486 | 0.080 |
Why?
|
Staining and Labeling | 2 | 2022 | 1101 | 0.080 |
Why?
|
DNA Primers | 2 | 2009 | 2891 | 0.070 |
Why?
|
Procarbazine | 2 | 1999 | 181 | 0.070 |
Why?
|
Risk Factors | 13 | 2019 | 72296 | 0.070 |
Why?
|
Interferon-gamma | 1 | 2016 | 3207 | 0.070 |
Why?
|
Melanocytes | 3 | 2017 | 515 | 0.070 |
Why?
|
Reoperation | 1 | 1997 | 4201 | 0.070 |
Why?
|
Genitalia, Male | 2 | 2017 | 84 | 0.070 |
Why?
|
Confidence Intervals | 1 | 2013 | 2971 | 0.070 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 2887 | 0.070 |
Why?
|
Phenotype | 4 | 2018 | 16367 | 0.070 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2012 | 985 | 0.070 |
Why?
|
Granzymes | 1 | 2008 | 271 | 0.070 |
Why?
|
Combined Modality Therapy | 5 | 1997 | 8642 | 0.070 |
Why?
|
Feasibility Studies | 3 | 2021 | 5077 | 0.070 |
Why?
|
Interferon Type I | 1 | 1990 | 542 | 0.070 |
Why?
|
Pyridines | 1 | 2018 | 2825 | 0.070 |
Why?
|
Analysis of Variance | 2 | 2013 | 6366 | 0.070 |
Why?
|
Glioblastoma | 2 | 1999 | 3481 | 0.070 |
Why?
|
Kidney | 3 | 2023 | 7184 | 0.070 |
Why?
|
Adenoma | 1 | 2017 | 2174 | 0.070 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2009 | 437 | 0.070 |
Why?
|
Pericardial Effusion | 1 | 1988 | 247 | 0.070 |
Why?
|
Odds Ratio | 5 | 2019 | 9849 | 0.070 |
Why?
|
Cell Line, Tumor | 6 | 2022 | 16690 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 6 | 2019 | 17446 | 0.070 |
Why?
|
Cohort Studies | 10 | 2019 | 40559 | 0.070 |
Why?
|
Leukopenia | 2 | 1997 | 213 | 0.070 |
Why?
|
Ovariectomy | 1 | 2008 | 661 | 0.070 |
Why?
|
Mice, Nude | 2 | 2010 | 3689 | 0.060 |
Why?
|
Transcription, Genetic | 3 | 2017 | 7721 | 0.060 |
Why?
|
Neoplastic Stem Cells | 1 | 2013 | 1376 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2018 | 15520 | 0.060 |
Why?
|
Epithelial Cells | 1 | 2017 | 3690 | 0.060 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2012 | 1821 | 0.060 |
Why?
|
Proteasome Endopeptidase Complex | 2 | 2010 | 1335 | 0.060 |
Why?
|
Lung | 2 | 2020 | 9857 | 0.060 |
Why?
|
Obesity | 3 | 2017 | 12746 | 0.060 |
Why?
|
Carbon Radioisotopes | 2 | 2018 | 577 | 0.060 |
Why?
|
Graft Rejection | 2 | 2008 | 4397 | 0.060 |
Why?
|
Pouchitis | 1 | 2005 | 62 | 0.060 |
Why?
|
RNA Interference | 2 | 2016 | 2890 | 0.060 |
Why?
|
Transcription Factors | 2 | 2015 | 12207 | 0.060 |
Why?
|
Contrast Media | 2 | 2022 | 5300 | 0.060 |
Why?
|
Epigenesis, Genetic | 1 | 2017 | 3646 | 0.060 |
Why?
|
Logistic Models | 3 | 2016 | 13409 | 0.060 |
Why?
|
Colorectal Neoplasms | 3 | 2012 | 6773 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2019 | 9955 | 0.060 |
Why?
|
Genotype | 6 | 2019 | 12952 | 0.060 |
Why?
|
Gene Rearrangement | 3 | 2019 | 1179 | 0.060 |
Why?
|
Research Design | 1 | 2020 | 5984 | 0.060 |
Why?
|
Severity of Illness Index | 4 | 2020 | 15535 | 0.060 |
Why?
|
Sialyltransferases | 1 | 2003 | 75 | 0.060 |
Why?
|
Double-Blind Method | 2 | 2017 | 12025 | 0.060 |
Why?
|
Body Mass Index | 4 | 2017 | 12721 | 0.060 |
Why?
|
Base Sequence | 3 | 2015 | 12797 | 0.060 |
Why?
|
Gene Expression Regulation, Enzymologic | 2 | 2009 | 1213 | 0.060 |
Why?
|
Oncogenes | 1 | 2009 | 1265 | 0.060 |
Why?
|
DNA-Binding Proteins | 2 | 2022 | 9647 | 0.050 |
Why?
|
Pancreatic Neoplasms | 2 | 2017 | 5263 | 0.050 |
Why?
|
Keratin-20 | 1 | 2022 | 31 | 0.050 |
Why?
|
Etoposide | 2 | 1996 | 641 | 0.050 |
Why?
|
Ileum | 1 | 2005 | 565 | 0.050 |
Why?
|
Fetus | 1 | 2010 | 1880 | 0.050 |
Why?
|
Genomics | 1 | 2018 | 5717 | 0.050 |
Why?
|
Paraganglioma, Extra-Adrenal | 1 | 2002 | 46 | 0.050 |
Why?
|
Diagnosis, Differential | 5 | 2022 | 12961 | 0.050 |
Why?
|
Translocation, Genetic | 2 | 2020 | 1420 | 0.050 |
Why?
|
SOXE Transcription Factors | 1 | 2022 | 57 | 0.050 |
Why?
|
Platinum | 1 | 2023 | 233 | 0.050 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2008 | 570 | 0.050 |
Why?
|
MART-1 Antigen | 1 | 2022 | 64 | 0.050 |
Why?
|
Lipids | 1 | 2013 | 3307 | 0.050 |
Why?
|
Lymphoproliferative Disorders | 1 | 2005 | 524 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2023 | 318 | 0.050 |
Why?
|
Cytomegalovirus Infections | 1 | 2008 | 820 | 0.050 |
Why?
|
Recurrence | 4 | 2013 | 8340 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2017 | 2504 | 0.050 |
Why?
|
Genetic Association Studies | 3 | 2019 | 2703 | 0.050 |
Why?
|
Probiotics | 1 | 2005 | 351 | 0.050 |
Why?
|
Epithelium | 2 | 2017 | 1679 | 0.050 |
Why?
|
Cysteine Endopeptidases | 2 | 2010 | 563 | 0.050 |
Why?
|
Infusions, Intravenous | 2 | 1997 | 2274 | 0.050 |
Why?
|
Vincristine | 2 | 1995 | 1039 | 0.050 |
Why?
|
Germ-Line Mutation | 2 | 2023 | 1788 | 0.050 |
Why?
|
Doxorubicin | 3 | 1995 | 2234 | 0.050 |
Why?
|
Tumor Microenvironment | 2 | 2023 | 3590 | 0.050 |
Why?
|
SOXB1 Transcription Factors | 1 | 2022 | 284 | 0.050 |
Why?
|
Chromosomes | 1 | 2024 | 596 | 0.050 |
Why?
|
Paclitaxel | 1 | 2008 | 1708 | 0.050 |
Why?
|
Cell Hypoxia | 2 | 2013 | 675 | 0.050 |
Why?
|
Multienzyme Complexes | 2 | 2010 | 686 | 0.050 |
Why?
|
Health Care Rationing | 1 | 2003 | 437 | 0.050 |
Why?
|
Cell Proliferation | 4 | 2019 | 10483 | 0.050 |
Why?
|
Cathepsin K | 1 | 2020 | 68 | 0.050 |
Why?
|
Disease-Free Survival | 2 | 2021 | 6896 | 0.040 |
Why?
|
Animals | 10 | 2022 | 168768 | 0.040 |
Why?
|
Nephrostomy, Percutaneous | 1 | 2020 | 85 | 0.040 |
Why?
|
Fibroblast Growth Factor 3 | 1 | 2019 | 17 | 0.040 |
Why?
|
Urinary Bladder Diseases | 1 | 2020 | 166 | 0.040 |
Why?
|
Thrombosis | 1 | 2013 | 2968 | 0.040 |
Why?
|
Child | 6 | 2020 | 77709 | 0.040 |
Why?
|
Germ Cells | 1 | 2023 | 631 | 0.040 |
Why?
|
Fixatives | 1 | 2018 | 94 | 0.040 |
Why?
|
Organ Transplantation | 2 | 2008 | 1140 | 0.040 |
Why?
|
Dermis | 1 | 2020 | 207 | 0.040 |
Why?
|
Tomography Scanners, X-Ray Computed | 1 | 2020 | 168 | 0.040 |
Why?
|
Safety | 1 | 2003 | 1186 | 0.040 |
Why?
|
Risk | 3 | 2016 | 9688 | 0.040 |
Why?
|
Chromosomes, Human, X | 1 | 2020 | 296 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 6234 | 0.040 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2020 | 323 | 0.040 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2019 | 417 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 250 | 0.040 |
Why?
|
Nomograms | 1 | 2019 | 228 | 0.040 |
Why?
|
STAT Transcription Factors | 1 | 2018 | 182 | 0.040 |
Why?
|
Diet | 1 | 2016 | 7937 | 0.040 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2018 | 224 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2018 | 20130 | 0.040 |
Why?
|
Janus Kinases | 1 | 2018 | 244 | 0.040 |
Why?
|
Genes, cdc | 1 | 1997 | 116 | 0.040 |
Why?
|
Enzyme Activation | 2 | 2015 | 3702 | 0.040 |
Why?
|
Fumarate Hydratase | 1 | 2016 | 47 | 0.030 |
Why?
|
Paresis | 1 | 1997 | 179 | 0.030 |
Why?
|
STAT4 Transcription Factor | 1 | 2016 | 96 | 0.030 |
Why?
|
Protein Stability | 1 | 2018 | 556 | 0.030 |
Why?
|
Protein Isoforms | 1 | 2021 | 1730 | 0.030 |
Why?
|
Laparoscopy | 2 | 2019 | 2150 | 0.030 |
Why?
|
Preoperative Period | 1 | 2018 | 550 | 0.030 |
Why?
|
Glucose Transporter Type 4 | 1 | 2016 | 250 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 1997 | 667 | 0.030 |
Why?
|
Glucose Transporter Type 1 | 1 | 2016 | 193 | 0.030 |
Why?
|
Patient Care | 1 | 2021 | 640 | 0.030 |
Why?
|
Germinoma | 1 | 1996 | 134 | 0.030 |
Why?
|
Cell Adhesion Molecules | 1 | 2022 | 1602 | 0.030 |
Why?
|
DNA Replication | 1 | 2022 | 1399 | 0.030 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2016 | 185 | 0.030 |
Why?
|
Microscopy | 1 | 2021 | 902 | 0.030 |
Why?
|
Hepatocytes | 1 | 2002 | 1211 | 0.030 |
Why?
|
Antigens, CD | 2 | 2005 | 4026 | 0.030 |
Why?
|
Cytokines | 2 | 2013 | 7323 | 0.030 |
Why?
|
Sarcoma | 2 | 2020 | 1897 | 0.030 |
Why?
|
Cell Cycle Proteins | 2 | 1997 | 3464 | 0.030 |
Why?
|
Mechlorethamine | 1 | 1995 | 136 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2017 | 793 | 0.030 |
Why?
|
Postoperative Complications | 4 | 2019 | 15297 | 0.030 |
Why?
|
Caco-2 Cells | 1 | 2016 | 387 | 0.030 |
Why?
|
Phosphoprotein Phosphatases | 1 | 1997 | 338 | 0.030 |
Why?
|
Actuarial Analysis | 1 | 1995 | 378 | 0.030 |
Why?
|
Hepatocyte Growth Factor | 1 | 2016 | 270 | 0.030 |
Why?
|
Cell Nucleus | 2 | 2016 | 2969 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2012 | 8949 | 0.030 |
Why?
|
Lymphatic Irradiation | 1 | 1995 | 103 | 0.030 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2015 | 374 | 0.030 |
Why?
|
Loss of Heterozygosity | 1 | 2017 | 684 | 0.030 |
Why?
|
Cytodiagnosis | 1 | 2018 | 435 | 0.030 |
Why?
|
Cytogenetic Analysis | 1 | 2015 | 295 | 0.030 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 1997 | 473 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 1997 | 6621 | 0.030 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 1 | 2014 | 30 | 0.030 |
Why?
|
Social Class | 1 | 2023 | 1997 | 0.030 |
Why?
|
Mice | 5 | 2022 | 81201 | 0.030 |
Why?
|
Tamoxifen | 1 | 1999 | 981 | 0.030 |
Why?
|
Cell Membrane | 2 | 2016 | 3749 | 0.030 |
Why?
|
Child, Preschool | 4 | 2017 | 41005 | 0.030 |
Why?
|
Urinary Tract | 1 | 2017 | 309 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2022 | 2007 | 0.030 |
Why?
|
Infusion Pumps | 1 | 1995 | 163 | 0.030 |
Why?
|
Age Factors | 3 | 2019 | 18373 | 0.030 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 1 | 2016 | 322 | 0.030 |
Why?
|
Immediate-Early Proteins | 1 | 1997 | 453 | 0.030 |
Why?
|
Intestinal Obstruction | 1 | 2017 | 423 | 0.030 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2016 | 625 | 0.030 |
Why?
|
Bleomycin | 1 | 1995 | 512 | 0.030 |
Why?
|
ras Proteins | 1 | 2019 | 1060 | 0.030 |
Why?
|
Spermatic Cord | 1 | 2013 | 25 | 0.030 |
Why?
|
Cyclophosphamide | 2 | 1991 | 2242 | 0.030 |
Why?
|
Residence Characteristics | 1 | 2023 | 2050 | 0.030 |
Why?
|
Pharmacogenetics | 1 | 2017 | 674 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2009 | 323 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 2016 | 709 | 0.030 |
Why?
|
Cyclin-Dependent Kinases | 1 | 1997 | 671 | 0.030 |
Why?
|
Vinblastine | 1 | 1995 | 502 | 0.030 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2015 | 658 | 0.030 |
Why?
|
T-Box Domain Proteins | 1 | 2016 | 471 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2022 | 1862 | 0.030 |
Why?
|
Rad51 Recombinase | 1 | 2013 | 189 | 0.030 |
Why?
|
Liver Function Tests | 2 | 2009 | 528 | 0.030 |
Why?
|
Infant, Newborn | 3 | 2017 | 25628 | 0.030 |
Why?
|
Bone Marrow Diseases | 1 | 1995 | 231 | 0.030 |
Why?
|
Cell Growth Processes | 1 | 2013 | 399 | 0.030 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2016 | 610 | 0.030 |
Why?
|
Autocrine Communication | 1 | 2013 | 171 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2018 | 850 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2019 | 9735 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2018 | 871 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2022 | 3759 | 0.030 |
Why?
|
Plant Extracts | 1 | 2016 | 471 | 0.030 |
Why?
|
alpha Catenin | 1 | 2012 | 38 | 0.030 |
Why?
|
Mass Screening | 1 | 2008 | 5253 | 0.030 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2015 | 415 | 0.030 |
Why?
|
Stathmin | 1 | 2012 | 71 | 0.030 |
Why?
|
Transurethral Resection of Prostate | 1 | 2012 | 83 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 1692 | 0.030 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2016 | 624 | 0.030 |
Why?
|
Dacarbazine | 1 | 1995 | 566 | 0.030 |
Why?
|
Metabolic Networks and Pathways | 1 | 2016 | 783 | 0.030 |
Why?
|
Keratin-19 | 1 | 2011 | 33 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 1997 | 1284 | 0.030 |
Why?
|
Keratin-7 | 1 | 2011 | 57 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2013 | 351 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 1997 | 1085 | 0.020 |
Why?
|
Thymus Gland | 1 | 1996 | 1267 | 0.020 |
Why?
|
Epididymis | 1 | 2013 | 227 | 0.020 |
Why?
|
Probability | 1 | 1997 | 2506 | 0.020 |
Why?
|
Histones | 2 | 2013 | 2598 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2015 | 841 | 0.020 |
Why?
|
Body Height | 1 | 2017 | 1578 | 0.020 |
Why?
|
Ifosfamide | 1 | 1991 | 228 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1525 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 1995 | 1572 | 0.020 |
Why?
|
Hedgehog Proteins | 1 | 2015 | 783 | 0.020 |
Why?
|
Microsatellite Instability | 1 | 2014 | 684 | 0.020 |
Why?
|
Lipoma | 1 | 2013 | 334 | 0.020 |
Why?
|
Anemia | 1 | 2020 | 1503 | 0.020 |
Why?
|
Hepatitis B | 1 | 1996 | 695 | 0.020 |
Why?
|
Treatment Failure | 1 | 1996 | 2618 | 0.020 |
Why?
|
Haplotypes | 1 | 2017 | 2779 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2003 | 3680 | 0.020 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2016 | 740 | 0.020 |
Why?
|
Endoscopy | 1 | 2020 | 1787 | 0.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2022 | 2737 | 0.020 |
Why?
|
Antibodies | 1 | 2018 | 2460 | 0.020 |
Why?
|
Liposarcoma | 1 | 2013 | 333 | 0.020 |
Why?
|
Heparin | 1 | 1997 | 1637 | 0.020 |
Why?
|
Prednisone | 1 | 1995 | 1574 | 0.020 |
Why?
|
Thyroidectomy | 1 | 2015 | 879 | 0.020 |
Why?
|
Waist Circumference | 1 | 2013 | 917 | 0.020 |
Why?
|
Serine | 1 | 2013 | 826 | 0.020 |
Why?
|
Piperidines | 1 | 2018 | 1602 | 0.020 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2013 | 644 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2023 | 7785 | 0.020 |
Why?
|
Fertilization in Vitro | 1 | 2017 | 1284 | 0.020 |
Why?
|
Pedigree | 1 | 2017 | 4642 | 0.020 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2015 | 806 | 0.020 |
Why?
|
Chronic Disease | 2 | 2017 | 9145 | 0.020 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2009 | 170 | 0.020 |
Why?
|
Drug Evaluation | 1 | 1990 | 647 | 0.020 |
Why?
|
Bromodeoxyuridine | 1 | 2009 | 322 | 0.020 |
Why?
|
Leukemia, Large Granular Lymphocytic | 1 | 2008 | 18 | 0.020 |
Why?
|
Ubiquitin-Conjugating Enzymes | 1 | 2009 | 195 | 0.020 |
Why?
|
Estradiol | 1 | 2016 | 2020 | 0.020 |
Why?
|
Pelvis | 1 | 2013 | 730 | 0.020 |
Why?
|
Tumor Cells, Cultured | 2 | 2009 | 6313 | 0.020 |
Why?
|
Codon | 1 | 2009 | 611 | 0.020 |
Why?
|
In Situ Nick-End Labeling | 1 | 2009 | 644 | 0.020 |
Why?
|
Leiomyoma | 1 | 2013 | 730 | 0.020 |
Why?
|
Incidental Findings | 1 | 2012 | 689 | 0.020 |
Why?
|
Fibrinolytic Agents | 1 | 1997 | 2158 | 0.020 |
Why?
|
United States | 4 | 2021 | 69872 | 0.020 |
Why?
|
Transaminases | 1 | 2008 | 200 | 0.020 |
Why?
|
Rectum | 1 | 2012 | 904 | 0.020 |
Why?
|
Mesothelioma | 1 | 2013 | 818 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 1995 | 1062 | 0.020 |
Why?
|
Body Weight | 1 | 2017 | 4671 | 0.020 |
Why?
|
Cell Division | 2 | 2009 | 4569 | 0.020 |
Why?
|
Life Style | 1 | 2018 | 3835 | 0.020 |
Why?
|
Bone and Bones | 1 | 2017 | 2576 | 0.020 |
Why?
|
Blood Platelets | 1 | 1997 | 2509 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1999 | 10943 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2009 | 1799 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2009 | 2943 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2015 | 2108 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5867 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 3508 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2010 | 2086 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2009 | 767 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2010 | 2505 | 0.020 |
Why?
|
Immunoblotting | 1 | 2009 | 1683 | 0.020 |
Why?
|
Protein Binding | 1 | 2018 | 9384 | 0.020 |
Why?
|
Injections | 1 | 1988 | 840 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2010 | 1879 | 0.020 |
Why?
|
Testosterone | 1 | 2016 | 2419 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2016 | 3511 | 0.020 |
Why?
|
Calcium | 1 | 2018 | 5755 | 0.020 |
Why?
|
Models, Biological | 2 | 2013 | 9584 | 0.020 |
Why?
|
Heme Oxygenase (Decyclizing) | 1 | 2005 | 171 | 0.020 |
Why?
|
Muscle Proteins | 1 | 2010 | 1158 | 0.020 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2011 | 1504 | 0.020 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 1 | 2004 | 66 | 0.020 |
Why?
|
Transfection | 1 | 2012 | 5895 | 0.020 |
Why?
|
Mice, SCID | 1 | 2010 | 2716 | 0.020 |
Why?
|
Rosaniline Dyes | 1 | 2004 | 51 | 0.020 |
Why?
|
Patient Compliance | 1 | 1995 | 2684 | 0.020 |
Why?
|
Linear Models | 1 | 2014 | 5953 | 0.010 |
Why?
|
Genetic Testing | 1 | 2017 | 3444 | 0.010 |
Why?
|
Tandem Repeat Sequences | 1 | 2005 | 185 | 0.010 |
Why?
|
Pericardium | 1 | 1988 | 667 | 0.010 |
Why?
|
Insulin | 1 | 2018 | 6582 | 0.010 |
Why?
|
Mitosis | 1 | 2009 | 1208 | 0.010 |
Why?
|
DNA Damage | 1 | 2013 | 2432 | 0.010 |
Why?
|
Prevalence | 1 | 2020 | 15221 | 0.010 |
Why?
|
Feeding Behavior | 1 | 2016 | 3188 | 0.010 |
Why?
|
Transcriptional Activation | 1 | 2009 | 1783 | 0.010 |
Why?
|
Tuberous Sclerosis | 1 | 2011 | 1029 | 0.010 |
Why?
|
Intraoperative Period | 1 | 2004 | 520 | 0.010 |
Why?
|
Vitronectin | 1 | 2002 | 44 | 0.010 |
Why?
|
Fluorescence | 1 | 2005 | 751 | 0.010 |
Why?
|
Mesenchymal Stem Cells | 1 | 2013 | 1632 | 0.010 |
Why?
|
Integrin alphaV | 1 | 2002 | 55 | 0.010 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2005 | 659 | 0.010 |
Why?
|
Heme Oxygenase-1 | 1 | 2005 | 381 | 0.010 |
Why?
|
Cell Survival | 1 | 2012 | 5882 | 0.010 |
Why?
|
Focal Nodular Hyperplasia | 1 | 2002 | 32 | 0.010 |
Why?
|
Multiprotein Complexes | 1 | 2009 | 1120 | 0.010 |
Why?
|
Gene Silencing | 1 | 2009 | 1539 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 1990 | 4933 | 0.010 |
Why?
|
Health Personnel | 1 | 2015 | 3219 | 0.010 |
Why?
|
Antigens, Differentiation | 1 | 2005 | 927 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2013 | 4424 | 0.010 |
Why?
|
Androgens | 1 | 2009 | 1281 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2009 | 2383 | 0.010 |
Why?
|
Infant | 2 | 2017 | 35134 | 0.010 |
Why?
|
Necrosis | 1 | 2004 | 1643 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2013 | 2987 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2010 | 3203 | 0.010 |
Why?
|
Glycosylation | 1 | 2003 | 1128 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 1990 | 6489 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2015 | 19233 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2009 | 3505 | 0.010 |
Why?
|
Organ Size | 1 | 2004 | 2251 | 0.010 |
Why?
|
Fibronectins | 1 | 2002 | 726 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2010 | 3778 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2009 | 5974 | 0.010 |
Why?
|
Software | 1 | 2012 | 4441 | 0.010 |
Why?
|
Vitamin D | 1 | 2011 | 3224 | 0.010 |
Why?
|
Physicians | 1 | 2015 | 4567 | 0.010 |
Why?
|
Dual Specificity Phosphatase 1 | 1 | 1997 | 44 | 0.010 |
Why?
|
Registries | 1 | 2012 | 8091 | 0.010 |
Why?
|
Protein Phosphatase 1 | 1 | 1997 | 137 | 0.010 |
Why?
|
Lymphoma | 1 | 2005 | 1877 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2008 | 2535 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2002 | 3144 | 0.010 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1997 | 494 | 0.010 |
Why?
|
Glycoproteins | 1 | 2003 | 2266 | 0.010 |
Why?
|
Pregnancy | 1 | 2017 | 29144 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 1997 | 480 | 0.010 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 1997 | 452 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2013 | 12073 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 1990 | 7914 | 0.010 |
Why?
|
Luteinizing Hormone | 1 | 1996 | 869 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2011 | 11486 | 0.010 |
Why?
|
Alleles | 1 | 2005 | 6933 | 0.010 |
Why?
|
Proteins | 1 | 2009 | 6100 | 0.010 |
Why?
|
Hyperplasia | 1 | 1996 | 1185 | 0.010 |
Why?
|
Incidence | 1 | 2011 | 20952 | 0.010 |
Why?
|
Neutrophils | 1 | 2005 | 3721 | 0.010 |
Why?
|
Genes, Tumor Suppressor | 1 | 1997 | 1097 | 0.010 |
Why?
|
Brain | 1 | 1999 | 26388 | 0.010 |
Why?
|
DNA | 1 | 2005 | 7294 | 0.010 |
Why?
|
Cell Movement | 1 | 2002 | 5218 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2009 | 18034 | 0.010 |
Why?
|
Gene Expression | 1 | 1997 | 7798 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1996 | 18111 | 0.000 |
Why?
|